JacobsWyper utilized our niche experience in nuclear medicine to lead a team of experts tasked with formulating a business case to consider options to secure the long-term and sustainable future of Australia's nuclear medicine supply.
This evaluation considered current, medium and long-term trends in the global radiopharmaceutical industry; and outlines options to provide a secure and sustainable future for the nuclear medicine supply in Australia. The business case will be submitted and presented to the ANSTO Board for their consideration, decision and submission to their Federal Government stakeholders.
JacobsWyper assembled an international team with extensive experience in the international radiopharmaceutical market, international supply chain logistics, and production. Including partnerships with Predict Inc: Independent consultancy led by Martyn Coombs, a recognized leader in Nuclear Medicine; previously President of Jubilant DraxImage and senior general management roles at Amersham, GE Healthcare and Nihon Medi-Physics. Other partners included Wood for input on infrastructure engineering and ONeal for input on process engineering.
